GoodRx (GDRX) Competitors

GoodRx (NASDAQ:GDRX) and Globant (NYSE:GLOB) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, community ranking, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.

Does the MarketBeat Community favor GDRX or GLOB?

Globant received 321 more outperform votes than GoodRx when rated by MarketBeat users. Likewise, 59.97% of users gave Globant an outperform vote while only 39.89% of users gave GoodRx an outperform vote.

Company	Underperform	Outperform
GoodRx	Outperform Votes 73 39.89%	Underperform Votes 110 60.11%
Globant	Outperform Votes 394 59.97%	Underperform Votes 263 40.03%

Do analysts rate GDRX or GLOB?

GoodRx currently has a consensus target price of $8.18, suggesting a potential upside of 79.67%. Globant has a consensus target price of $219.71, suggesting a potential upside of 69.54%. Given GoodRx's stronger consensus rating and higher probable upside, analysts plainly believe GoodRx is more favorable than Globant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.80
Globant	0 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.71

Do insiders & institutionals have more ownership in GDRX or GLOB?

63.8% of GoodRx shares are held by institutional investors. Comparatively, 91.6% of Globant shares are held by institutional investors. 4.2% of GoodRx shares are held by company insiders. Comparatively, 2.7% of Globant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the media refer more to GDRX or GLOB?

In the previous week, Globant had 2 more articles in the media than GoodRx. MarketBeat recorded 8 mentions for Globant and 6 mentions for GoodRx. GoodRx's average media sentiment score of 1.60 beat Globant's score of 0.84 indicating that GoodRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GoodRx	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Globant	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GDRX or GLOB more profitable?

Globant has a net margin of 6.86% compared to GoodRx's net margin of -2.05%. Globant's return on equity of 11.83% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	-2.05%	5.35%	2.51%
Globant	6.86%	11.83%	8.09%

Which has more risk and volatility, GDRX or GLOB?

GoodRx has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Globant has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Which has higher valuation and earnings, GDRX or GLOB?

Globant has higher revenue and earnings than GoodRx. Globant is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$792.32M	2.20	-$8.87M	$0.05	91.00
Globant	$2.42B	2.36	$158.54M	$3.72	34.84

Summary

Globant beats GoodRx on 14 of the 19 factors compared between the two stocks.